STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
批准号:
10005721
负责人:
James K Turkson
金额:
$26.28万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-01 至 2022-02-28
中文摘要
多形性胶质母细胞瘤和乳腺癌是主要的健康负担,将受益于新的
机械的洞察力,导致新的管理战略。我们建议对信号进行调查
转录转导和激活因子(STAT)3、硫氧还蛋白还原酶(TrxR)1胞浆异构体3、
和葡萄糖-6-磷酸1-脱氢酶(G6PD)亚型作为潜在的靶向机制
基底膜和三阴性乳腺癌对毛状内酯类化合物的抗肿瘤作用。毛刺素内酯
系列是灰斑潜蝇的主要化学成分。这种植物传统上被用于
亚洲将治疗特定疾病,临床试验证明对中度2型糖尿病和
减少吸烟。尽管水飞蓟内酯具有治疗潜力,但人们对其知之甚少。
药理特性,以促进其临床发展,直到我们的研究。我们令人信服的数据
表明结构上合适的毛糖素内酯强烈抑制STAT3、TrxR1和G6PD功能,从而
在体外和体内抑制乳腺癌和基底膜表型。初始结构活性关系
分析表明,这些活动需要一个13位酯基团。不偏不倚
计算模拟/对接和核磁共振结构研究表明,在结构上
合适的毛囊素内酯通过STAT3DNA结合域(DBD)与STAT3DNA结合域(DBD)之间的疏水相互作用结合
STAT3DBD中第13位侧链和特定氨基酸残基。选择引起的化合物
有丝分裂和细胞周期阻断和抑制人乳腺癌和GBM异种移植瘤的生长。与…一致
TrxR1或G6PD在细胞过氧化损伤保护中的作用
用于NADPH产生的活性氧物种(ROS)或戊糖磷酸途径中,
ROS水平和糖酵解代谢产物,包括葡萄糖、G6P和丙酮酸,在
水飞蓟素内酯治疗的肿瘤细胞。我们假设结构上合适的毛状内酯具有天然的活性。
抗STAT3、TrxR1和G6PD功能,改变细胞氧化还原事件和糖酵解代谢,以及
从而阻止乳腺癌和基底膜的进展。我们将测定水飞蓟内酯的相对分子质量。
为了抑制STAT3活性并阐明抑制STAT3的结构决定因素(目标1),
探讨水飞蓟素内酯抑制STAT3信号转导的机制及其意义
针对GBM和乳腺癌的抗肿瘤反应(目标2),确定了
STAT3、TrxR1和G6PD功能,改变细胞氧化还原循环、代谢、有丝分裂和细胞周期(AIM
3),并研究选定的水飞蓟内酯类似物的抗肿瘤效应及其与STAT3的相关性,
体内依赖TrxR1和G6PD的分子和代谢事件(目标4)。数据最终将
促进毛状内酯作为乳腺癌和基底膜的潜在治疗药物的开发。
英文摘要
Glioblastoma multiforme (GBM) and breast cancer are major health burdens that will benefit from new
mechanistic insights that lead to novel management strategies. We propose to investigate Signal
Transducer and Activator of Transcription (STAT)3, thioredoxin reductase (TrxR)1 cytoplasmic isoform 3,
and glucose-6-phosphate 1-dehydrogenase (G6PD) isoform a as the targeting mechanisms underlying the
antitumor responses of GBM and triple-negative breast cancer to hirsutinolide compounds. The hirsutinolide
series are the major chemical constituents of Vernonia cinerea. This plant has traditionally been used in
Asia to treat specific ailments and in clinical trials proofed to be effective to moderate type 2 diabetes and
curtail smoking. Despite the therapeutic potential of the hirsutinolides, however, little was known of their
pharmacological properties to facilitate their clinical development until our studies. Our compelling data
show that structurally suitable hirsutinolides strongly inhibit STAT3, TrxR1 and G6PD functions and thereby
suppress breast cancer and GBM phenotypes in vitro and in vivo. Initial structure activity relationship
analysis showed a critical requirement for a position 13 ester group for the activities. Unbiased
computational modeling/docking and nuclear magnetic resonance structural studies show that structurally
suitable hirsutinolides bind the STAT3 DNA-binding domain (DBD) via hydrophobic interactions between the
position 13 side chain and specific amino acid residues in the STAT3 DBD. Select compounds caused
mitotic and cell cycle arrests and inhibited growth of human breast cancer and GBM xenografts. In line with
the TrxR1 or G6PD functional roles in the cellular protection against the oxidative damage from excessive
reactive oxygen species (ROS) or in the pentose phosphate pathway for NADPH production, respectively,
ROS levels and glycolytic metabolites, including glucose, G6P and pyruvate are significantly altered in
hirsutinolide-treated tumor cells. We hypothesize that structurally suitable hirsutinolides are inherently active
against STAT3, TrxR1 and G6PD functions, and alter cellular redox events and glycolytic metabolism, and
thereby block breast cancer and GBM progression. We will determine the SAR of the hirsutinolides relative
to inhibition of STAT3 activity and elucidate the structural determinants for STAT3 inhibition (Aim 1),
investigate the mechanistic details of the STAT3 signaling inhibition by hirsutinolides and the significance to
the antitumor responses against GBM and breast cancer (Aim 2), define the mechanistic link between
STAT3, TrxR1 and G6PD functions, altered cellular redox recycle, metabolism, mitosis and cell cycle (Aim
3), and study the antitumor efficacy responses of select hirsutinolide analogs and their correlation to STAT3,
TrxR1 and G6PD-dependent molecular and metabolomic events in vivo (Aim 4). Data will ultimately
facilitate the development of the hirsutinolides as potential therapeutics for breast cancer and GBM.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
11th Annual Meeting of International Cytokine & Interferon Society
-
批准号:10753947
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2023
-
负责人:James K Turkson
-
依托单位:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses to hirsutinolides
-
批准号:9443606
-
项目类别:
-
资助金额:$50.27万
-
财政年份:2017
-
负责人:James K Turkson
-
依托单位:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
-
批准号:10098001
-
项目类别:
-
资助金额:$54.99万
-
财政年份:2017
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8370490
-
项目类别:
-
资助金额:$48.94万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8770667
-
项目类别:
-
资助金额:$7.81万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8676474
-
项目类别:
-
资助金额:$46.78万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8519385
-
项目类别:
-
资助金额:$42.39万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8856165
-
项目类别:
-
资助金额:$48.06万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:9069481
-
项目类别:
-
资助金额:$48.06万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
-
批准号:7526222
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2008
-
负责人:James K Turkson
-
依托单位:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
-
批准号:8115186
-
项目类别:
-
资助金额:$22.39万
-
财政年份:2008
-
负责人:James K Turkson
-
依托单位:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
-
批准号:7685297
-
项目类别:
-
资助金额:$18.2万
-
财政年份:2008
-
负责人:James K Turkson
-
依托单位:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
-
批准号:7903970
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2008
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:6870436
-
项目类别:
-
资助金额:$11.25万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7336340
-
项目类别:
-
资助金额:$23.53万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7018427
-
项目类别:
-
资助金额:$24.28万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7216350
-
项目类别:
-
资助金额:$23.53万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7123704
-
项目类别:
-
资助金额:$17.34万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7547751
-
项目类别:
-
资助金额:$23.53万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
国内基金
海外基金
登录
查看更多内容
UDCA抑制G6PD活性诱导 HCC 细胞铁死亡的抗肝癌机制研究
-
批准号:2026JJ82280
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:熊玉婕
-
依托单位:
HCP5调控G6PD泛素化降解介导肺腺癌奥希替尼耐药的作用及机制研究
-
批准号:2026JJ81745
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:王子尧
-
依托单位:
G6PD通过SYK/JNK通路调节破骨分化缓解绝经后骨质疏松症的作用机制
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:彭志
-
依托单位:
DDX27 通过双重调控 G6PD抑制铁死亡而促进结直肠癌
增殖及耐药的机制
-
批准号:2024JJ6663
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:伍至维
-
依托单位:
地高辛通过抑制G6PD表达逆转FLT3/ITD突变的AML细胞对索拉非尼耐药的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:曾佩婷
-
依托单位:
G6PD SUMO1修饰应答氧化应激调控糖代谢促进肝癌恶性进程机制研究
-
批准号:32370829
-
项目类别:面上项目
-
资助金额:50万元
-
批准年份:2023
-
负责人:边学利
-
依托单位:
HBx介导染色质可及性激活ETV4/G6PD轴促进肝癌生长作用机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:
-
依托单位:
G6PD缺乏导致血管内皮细胞糖代谢重编程引起颅内动脉粥样硬化性狭窄的机制研究
-
批准号:82371308
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:曾进胜
-
依托单位:
防风草通过调控G6PD Lys403乙酰化/PPP异常活化途径介导的肾小管上皮细胞代谢重编程抑制肾脏纤维化的机制研究
-
批准号:82374198
-
项目类别:面上项目
-
资助金额:48万元
-
批准年份:2023
-
负责人:龙海波
-
依托单位:
Glut1/ALDOB/G6PD代谢轴通过重塑糖代谢调控PDAC耐药性的机制探究
-
批准号:82303257
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:李允广
-
依托单位: